Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sujay Srinivas

Showing results (1-10 of 47) with videos related to

Pageof 5
Sort By:
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Checkpoint Inhibitors in Checkmating Rare CancersSujay Srinivas, Jyoti Bajpai
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Immunotherapy in Special and Rare Situations: A Brief ReviewSujay Srinivas, Jyoti Bajpai
Journal of Family Medicine and Primary Care|September 27, 2021
Utility of Panfungal PCR in the diagnosis of invasive fungal infections in febrile neutropeniaSujay Srinivas, Pushpa Kumari, Dipendra Kumar Gupta
Indian Journal of Cancer|January 4, 2019
Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?Anant Ramaswamy, Vikas Ostwal, Alok Goel, et al.
Ecancermedicalscience|June 10, 2022
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)-basis and current statusAnant Ramaswamy, Sujay Srinivas, Vikram Chaudhari, et al.
South Asian Journal of Cancer|December 31, 2025
Practice Patterns and Incidence of <b>F</b> ebrile Neutr <b>o</b> penia in Patients <b>R</b> eceiving <b>T</b> riplet Drug Chemotherapeutic Regimens in <b>G</b> U <b>T</b> Cancers: Do We Need to Add WBC Growth Factors? (ForGeT GCSF Study)Kapu Venkatesh, Anant Ramaswamy, Noorzia Sultana, et al.
Indian Journal of Cancer|January 4, 2019
Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in IndiaAnant Ramaswamy, Sangeetha Parthiban, Mridul Malhotra, et al.
The Indian Journal of Medical Research|April 11, 2023
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysisAnant Ramaswamy, Darshit Shah, Prabhat Bhargava, et al.
South Asian Journal of Cancer|June 18, 2021
Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?Akhil Kapoor, Ashutosh Jain, Abhishek Sharma, et al.
Journal of Cancer Research and Therapeutics|March 30, 2024
Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomesRamjas Prajapati, Vikas Ostwal, Sujay Srinivas, et al.
Pageof 5

Showing results (1-10 of 47) with videos related to

Sort By:
Pageof 5
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Checkpoint Inhibitors in Checkmating Rare CancersSujay Srinivas, Jyoti Bajpai
Journal of Immunotherapy and Precision Oncology|June 6, 2022
Immunotherapy in Special and Rare Situations: A Brief ReviewSujay Srinivas, Jyoti Bajpai
Journal of Family Medicine and Primary Care|September 27, 2021
Utility of Panfungal PCR in the diagnosis of invasive fungal infections in febrile neutropeniaSujay Srinivas, Pushpa Kumari, Dipendra Kumar Gupta
Indian Journal of Cancer|January 4, 2019
Treatment practices for metastatic pancreatic cancer: Can we deliver an appropriately efficacious and safe regimen in Indian patients?Anant Ramaswamy, Vikas Ostwal, Alok Goel, et al.
Ecancermedicalscience|June 10, 2022
Systemic therapy in pancreatic ductal adenocarcinomas (PDACs)-basis and current statusAnant Ramaswamy, Sujay Srinivas, Vikram Chaudhari, et al.
South Asian Journal of Cancer|December 31, 2025
Practice Patterns and Incidence of <b>F</b> ebrile Neutr <b>o</b> penia in Patients <b>R</b> eceiving <b>T</b> riplet Drug Chemotherapeutic Regimens in <b>G</b> U <b>T</b> Cancers: Do We Need to Add WBC Growth Factors? (ForGeT GCSF Study)Kapu Venkatesh, Anant Ramaswamy, Noorzia Sultana, et al.
Indian Journal of Cancer|January 4, 2019
Outcomes with second-line chemotherapy in advanced pancreatic cancers: A retrospective study from a tertiary cancer center in IndiaAnant Ramaswamy, Sangeetha Parthiban, Mridul Malhotra, et al.
The Indian Journal of Medical Research|April 11, 2023
Modified FOLFIRINOX compared to Gemcitabine & nab-Paclitaxel in advanced pancreatic ductal adenocarcinoma - results of a match-pair analysisAnant Ramaswamy, Darshit Shah, Prabhat Bhargava, et al.
South Asian Journal of Cancer|June 18, 2021
Chemotherapy-Induced Nausea and Vomiting in Gastrointestinal Cancer Patients: Do We Need to Revisit Guidelines?Akhil Kapoor, Ashutosh Jain, Abhishek Sharma, et al.
Journal of Cancer Research and Therapeutics|March 30, 2024
Modified FOLFIRINOX (mFOLFIRINOX) as neoadjuvant therapy and 'salvage' in patients with high risk locally advanced rectal cancers - tolerance and early outcomesRamjas Prajapati, Vikas Ostwal, Sujay Srinivas, et al.
Pageof 5